GlobeNewsWire
05 Aug 2026, 23:45 UTC · 1h ago
UPDATE - LifeMD Reports Second Quarter 2026 Results
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
GlobeNewsWire
05 Aug 2026, 23:45 UTC · 1h ago
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
What the story claims
5 claims · each scored for market impact
LifeMD expects to exit 2026 with an annualized revenue run rate of approximately $250 million and annualized adjusted EBITDA of $22 million. — Provides concrete, forward-looking growth targets and profitability benchmarks for investors to value the company.
+0.60Adjusted EBITDA for the second quarter finished below the company's previously provided guidance range. — Missing profitability targets typically triggers negative short-term sentiment regarding management's execution or cost control.
-0.40The share of new weight management patients selecting multi-month packages increased from 25% to 85% following a pricing change. — Significantly increases predictable recurring revenue and improves customer lifetime value (LTV).
+0.40Continue reading
6 related stories
Top 1 mover · tap to explore
Gross margin expanded to approximately 89% due to lower fulfillment costs and scaling of the in-house pharmacy. — Demonstrates operational efficiency and the ability to capture more of the value chain via vertical integration.
+0.30The transition to branded GLP-1 medications has weighed on near-term profitability. — Indicates a margin squeeze due to the higher cost of branded pharmaceutical therapies compared to alternatives.
-0.20Which stocks this story touches
The company is mentioned as a collaborator in the launch of XYOSTED, which is listed as a priority for growth.
While adjusted EBITDA missed guidance, the company reported strong gross margins, a growing recurring revenue base, and a positive outlook for the second half of 2026.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
How the impact breaks down
Where the story's weight lands
Stocks most exposed
Modeled from each name's sensitivity to this story
24/7 Wall Street
1h ago
